- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Longport wins first LDS order
Ultrasound developer Longport of Swarthmore, PA, has received its first commercial order for its Longport Digital Scanner (LDS), a portable ultrasound scanner that captures and reproduces images of soft tissue down to 2 cm (SCAN 1/13/99). The
Ultrasound developer Longport of Swarthmore, PA, has received its first commercial order for its Longport Digital Scanner (LDS), a portable ultrasound scanner that captures and reproduces images of soft tissue down to 2 cm (SCAN 1/13/99). The order is for 25 of the systems, and comes from UltraScan East of Allentown, PA.
The order is the latest good news for the company. In April, Longport signed an agreement with Healthlink International of Westerville, OH, in which Healthlink will invest $5 million to support Longports R&D efforts (SCAN 5/26/99). The firm then received clearance for LDS from the Food and Drug Administration in June. In September, Longport formed an international subsidiary to begin worldwide marketing of LDS, and applied for listing on the Pacific Stock Exchange.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
